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A trial fibrillation (AF) is a global problem with a significantimpact on health outcomes, affecting up to 1% to 2% of
the global adult population, and is projected to increase in
both developed and developing countries over the coming
decades.1 AF is associated with higher mortality and morbid-
ity, as well as decreased quality of life, and increases the risk
of thromboembolic events (including stroke), heart failure
(HF), myocardial infarction, dementia, and chronic kidney
disease. The mainstays of AF treatment are arrhythmia
management (with pharmacologic or mechanical rate or
rhythm control) and prevention of thromboembolism.2 The
field of AF treatment is dynamic, with the recent develop-
ment of new procedures to restore sinus rhythm (catheter
and surgical ablation) and new treatments to reduce
thromboembolism (target-specific oral anticoagulants and
catheter-based exclusion of the left atrial appendage). How-
ever, there is significant global variation in use of these
therapies, particularly in developing countries, and the global
implementation, diffusion, and anticipated real-world effec-
tiveness of these technologies is uncertain.3 Therefore, a
better understanding of global AF treatments, barriers and
facilitators to its optimal use, and its subsequent outcomes is
needed.
As AF incidence and its arsenal of treatments continue to
expand globally, the longitudinal and comprehensive nature of
clinical registries can provide important insights into the
clinical management of AF. Registries are observational
databases of clinical conditions and/or therapies in which
there are no mandated approaches to therapy and relatively
few inclusion or exclusion criteria.4 In addition, registries can
continuously collect longitudinal data on their target popula-
tion, which allows them to monitor current and emerging
clinical practices over time and associate them with clinical
outcomes. Accordingly, current AF management practices and
their associated outcomes can be measured, benchmarked to
current best practices and clinical practice guidelines, and
compared across different countries, populations, and health-
care systems. As novel AF treatments emerge, their dissem-
ination globally and effect on outcomes, both intended and
unintended, can be assessed.
Currently, multiple AF databases and registries spanning
a variety of countries, patients, treatments, and outcomes
exist.5 However, coordination among these data sources is
minimal. In addition, the variations in patient enrollment,
data definitions, and characterization of AF therapies in each
of the registries prevent effective comparison between
registries and limit their ability to track changes over time.
Finally, many of the current registries are sponsored by
pharmaceutical or device companies, which can limit their
focus on those patients and treatments associated with their
products.
The potential value of coordinating these disparate
registry efforts is significant. More accurate and complete
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SPECIAL REPORT
assessment of the treatment and outcomes of AF in various
countries and populations around the world could occur. As
the arsenal of AF treatments continues to expand, such a
registry would allow for comparative effectiveness studies
between treatments. Additionally, a global registry would
allow for understanding of the impact of treatments in
various patient populations and within the context of their
local healthcare environments. Large registries could also
utilize their size to detect infrequent, but important, safety
signals of both AF and its treatment. Thus, the insights from
such a registry effort could allow for richer insights into AF
and sharing of best practices for its management. In
addition, these insights could inform ongoing research
efforts, supporting a “learning healthcare system” iterative
cycle of knowledge generation from clinical practice
insights.6
To respond to this need, we present the International
Collaborative Partnership for the Study of Atrial Fibrillation
(INTERAF). This worldwide partnership, with initial participants
from the United States, Europe, China, Brazil, South Korea,
Taiwan, Singapore, Japan, and the Balkan countries, provides
a common platform for investigators and countries to study
AF populations, treatments, and outcomes. In order to allow
for the integration of registries from a wide variety of
countries, INTERAF utilizes a distributed data and analytic
platform, rather than a single, combined registry structure.
The INTERAF leadership provides general data requirements,
standards, and governance policies for existing and future
country- and region-specific registries. This design allows for
easier integration of pre-existing registries and greater
flexibility in data collection, which can lower barriers to
participation, allow for an expansive view of global AF
treatment and outcome patterns, and support country-
specific and international efforts to optimize the care for
the large and growing population of AF patients.
In this report, we present the current knowledge and gaps
in global AF management and outcomes, and discuss how
INTERAF can fill these gaps. We also outline the organizing
principles and structure of the INTERAF partnership, and
introduce its initial research agenda and future directions.
Finally, we provide initial descriptive data of the participating
registries and their AF populations.
Global AF Prevalence and Projections for
Growth
AF is a global problem, with projections for significant growth
in the coming years. Although comprehensive data are
lacking, the 2010 Global Burden of Disease study provides
some insights, suggesting that the total number of AF patients
is 33 million, with an age-adjusted prevalence of 596 per
100 000 men and 373 per 100 000 women, with significant
regional variation (Figure 1).1,7
Over the coming years, AF prevalence is expected to grow
significantly. Current census projections for 2050 suggest
that the number of Americans, Europeans, and Japanese with
AF will increase by 2- to 3-fold.1 In addition, the number of
people in the developing world who are older than 60 years,
where AF incidence is concentrated, is projected to double by
2050 (Figure 2).1
Figure 1. International age-adjusted AF prevalence rates (per 100 000 population) in the 21 Global Burden of Disease regions, 2010.
Figure reproduced from Chugh et al7 with permission from Wolters Kluwer Health, Inc. AF indicates atrial fibrillation.
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Associations Between AF and Mortality,
Morbidity, and Quality of Life
AF is associated with increased mortality. As AF prevalence
and average lifespan increases over time, this burden will
likely increase as well. In adjusted analyses from the
Framingham Heart Study in the United States, AF was
associated with a 50% higher risk of death among men (odds
ratio 1.5, 95% CI 1.2–1.8) and a 90% higher risk of death
among women (odds ratio 1.9, 95% CI 1.5–2.2).8 Globally, the
age-adjusted mortality rate, per 100 000 individuals, from AF
in 2010 was 1.6 (95% CI 1–2.4) among men and 1.7 (95% CI
1.4–2.2) among women, representing a 2-fold increase since
the previous survey conducted in 1990.7 Perhaps surprisingly,
AF mortality rates in the developed world were 3 to 4 times
higher than the developing world (Figure 3).
AF is also associated with significant morbidity. One of the
most devastating consequences of AF is arterial thromboem-
bolism. AF is associated with a 4 to 5 times higher risk of
stroke, even after accounting for standard stroke risk factors
(eg, hypertension, congestive HF, etc).9,10 However, this risk
of thromboembolism and its subsequent outcomes vary
significantly among ethnic groups and geographies. For
example, Americans of either Hispanic ethnicity or African-
American race appear to have higher stroke risks, despite a
lower prevalence of AF relative to white individuals.8,11 Asians
with AF may have particularly high risks for stroke, potentially
due to variations in both anticoagulant prescribing practices
and variable genetic-based responses to anticoagulation with
warfarin.12–15 Similar variation in thromboembolism risk and
outcomes may also occur in other regions, but comprehensive
global assessments of thromboembolism outcomes, particu-
larly in developing countries, are lacking.
Figure 2. Global AF prevalence and projected increases.
Figure reproduced from Rahman et al1 with permission from
Nature Publishing Group. AF indicates atrial fibrillation.
Figure 3. Mortality associated with atrial fibrillation (AF) stratified by sex and type of region (developed vs developing). Figure reproduced
from Chugh et al7 with permission from Wolters Kluwer Health, Inc.
DOI: 10.1161/JAHA.116.004037 Journal of the American Heart Association 3
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AF is also associated with other causes of morbidity,
including coronary artery disease, dementia, chronic kidney
disease, and HF. Coronary artery disease has been associated
with AF across a wide variety of ethnicities and coun-
tries.3,10,16–18 A US-based study found that AF was associated
with a 70% increased risk of incident myocardial infarction
(hazard ratio, 1.96; 95% CI, 1.52, 2.52), with higher risks in
women and blacks.19 AF has also been associated with
cognitive decline and dementia. A meta-analysis of 21 studies
found decreased cognitive scores associated with AF in
different populations.11 In Brazil, AF patients were 2.8 times
more likely to have dementia, relative to those without AF.14
AF also is associated with chronic kidney disease. A US-based
study noted that the development of new-onset AF in chronic
kidney disease patients was associated with a 1.7 times
increased risk of developing end-stage renal disease, relative
to those without AF.15 Similarly, a Japanese study found the
incidence of kidney dysfunction was 18.2 per 1000 person-
years in AF patients, compared to 6.8 per 1000 person-years
in patients without AF.20 Finally, HF among AF patients is
common, occurring in 40% of patients, and associated with
increased morbidity and mortality.12 These associations
between AF and HF in the developed world have also been
demonstrated in the developing world. In particular, African
studies have documented a 10% to 20% prevalence of AF
among patients admitted to hospitals with HF.13
These associations between AF, mortality, and morbidity
impair overall quality of life. This effect can be estimated by a
disability-adjusted life years calculation, which adds up the
years lost due to the condition with the years lived with the
condition, weighted for its impact on quality of life.9 As
illustrated in Figure 4, AF-associated DALYs have consistently
increased over the past 2 decades and continued increases
are projected for the coming year.7
Although these data underscore the impact that AF has on
mortality, morbidity, and quality of life, a full assessment of its
worldwide impact is lacking. The INTERAF initiative can
address these gaps, and uncover additional insights into the
impact of AF globally.
Global Trends and Differences in AF
Treatments
There are notable variations in AF treatment and outcomes
between different patient and country populations. Some of this
variation is due to the availability of medications and interven-
tions that, in turn, are dependent on resource availability and
differences in healthcare systems (eg, national healthcare
systems, private health insurance, or a mixture of both). In
general, AF treatments are directed towards symptom reduc-
tion, typically via heart rate or rhythm control, and the
prevention of complications, such as arterial thromboem-
bolism. Rate and/or rhythm-control treatments include heart
rate controlling medications, antiarrhythmic medications,
electrical cardioversion, or AF ablation. Thromboembolism
prevention treatments include antithrombotic medications and
mechanical left atrial appendage occlusion devices.
The use of rate and rhythm-control treatments varies
globally, both in the developed and developing world. In the
Euro Heart Survey, 65% of AF patients received rate-control
medication, 40% received antiarrhythmic medication, and 12%
received neither.21 In contrast, a German AF registry—the
Central Registry of German Competence Network on Atrial
Fibrillation (AFNET)—demonstrated that only 21.3% of
patients received antiarrhythmic medication, but 53.4%
received electrical or pharmacologic cardioversion and 5%
underwent AF ablation.22 Chinese data demonstrated variable
use of rate-control treatments, partly dependent on the AF
phenotype.23,24 Among those with paroxysmal AF, 44% of
patients received rate-control treatment, compared to 83% of
patients with permanent AF. These differences likely result
from a variety of factors, including availability of more
advanced and technically complex treatments, such as AF
ablation.25 In the developing world, rate-control treatments,
particularly digoxin, dominate the use of antiarrhythmic
medications, given their low cost and wide availability. For
example, recent surveys of AF treatments in Cameroon found
that 83% of patients were being treated with rate-control
medications, with over 60% receiving digoxin.26 Similarly, over
50% of Kenyan patients on rate-control therapy were receiving
digoxin.27 However, better characterization of rate-control
Figure 4. Disability-adjusted life years (DALYs) related to AF.
Estimated global age-adjusted DALYs (per 100 000) related to
atrial fibrillation: 1990 to 2010. UI indicates uncertainty index.
Figure reproduced from Chugh et al7 with permission from Wolters
Kluwer Health, Inc.
DOI: 10.1161/JAHA.116.004037 Journal of the American Heart Association 4
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treatments, especially in developing countries, is needed. In
addition, as newer technologies such as AF ablation gain
traction in these countries, registries will be needed to guide
their safe and effective deployment.
Thromboembolic events related to AF are significantly
reduced with the use of anticoagulation therapies. However,
large variations occur in its provision and effect among
various populations. For example, despite the recommenda-
tion that patients at moderate to high risk for thromboem-
bolism receive anticoagulation, large numbers of patients,
across multiple countries, do not.3,21,28 Furthermore, even
among those patients receiving anticoagulation with warfarin,
its use is often suboptimal, with several studies demonstrat-
ing significant rates of subtherapeutic warfarin levels globally,
particularly in developing countries.29,30 Finally, certain pop-
ulations appear to have higher risks of significant bleeding
with anticoagulation, thus diminishing its benefit. In particular,
Asian, Hispanic, and black populations all appear to have
higher rates of intracranial hemorrhage on oral anticoagula-
tion (OAC), relative to white populations.31,32
In recent years, 2 new modalities for thromboembolism
prevention have emerged: direct oral anticoagulants (DOACs)
and left atrial appendage occlusion devices. There is a need to
understand how these new therapies will diffuse into global
practice, and their impact on both thromboembolic event
prevention and bleeding outcomes. DOACs have similar or
better efficacy than warfarin, and have a dose-dependent,
predictable anticoagulant effect, thus enabling fixed dosing
that does not require laboratory monitoring of anticoagulation
intensity. In addition, DOACs have a favorable safety profile,
particularly for intracranial hemorrhage. All of these charac-
teristics are potentially attractive to regions with relatively
underdeveloped healthcare systems. However, DOACs are
more expensive than warfarin and, with the exception of
dabigatran, cannot be easily reversed.33 These factors may
limit their dissemination to the developing world. Left atrial
appendage occlusion devices are an option for those patients
who have absolute contraindications to OAC or completely
refuse OAC, and appear to have similar efficacy to OAC in
thromboembolism prevention.34 However, the safety of left
atrial appendage occlusion device implantation is largely
operator dependent, with better outcomes in those who
perform a high number of procedures. Thus, technical
complexity, as well as cost, will likely slow its dissemination
to the developing world. Registries to monitor its dissemina-
tion and safety of these new therapies are needed.35
The International Collaborative Partnership
for the Study of Atrial Fibrillation (INTERAF)
In response to this need for a more coordinated approach to
AF registries, the International Collaborative Partnership for
the Study of Atrial Fibrillation (INTERAF) was established.
Organized by an international group of AF and clinical registry
experts, INTERAF is a collaborative, international consortium
of AF registries to characterize worldwide AF care and
establish a foundation for ongoing efforts to optimize AF care.
The goals of INTERAF are 4-fold:
1. Build the foundation for a sustained international collabo-
ration to identify and address meaningful questions related
to AF management and improve AF patient outcomes.
2. Explore ways to harmonize existing and future AF
registries in order to compare AF care across countries,
identify gaps, and to influence and change global practice
to close those gaps.
3. Prioritize research projects focused on international qual-
ity improvement.
4. Develop a roadmap for global AF quality improvement and
educational initiatives, informed by best practices.
The initial partners of INTERAF include representatives
from the United States, Europe, China, Brazil, South Korea,
Taiwan, Singapore, Japan, and the Balkan countries (Figure 5).
Each of the partners oversees country- or region-specific AF
registries, and can thus inform efforts to unify their respective
registries. In addition, the countries represent a variety of
patient populations and healthcare systems, which can inform
the technical challenges inherent in creating a unified, global
AF registry. Table 1 lists the participating registries and their
various characteristics.
A challenge for all clinical registries, particularly those that
are global in scope, is organizing data collection and analytic
efforts to gain meaningful insights. Simply establishing a single
registry that collects the same data elements in every
participating country is not feasible, given the enormous costs
and logistical difficulties associatedwith such an effort. Instead,
INTERAF will be organized as a distributed research network,
similar to the National Heart, Lung, and Blood Institute–
supported Cardiovascular Research Network and the Patient-
Centered Outcomes Research Institute (PCORI)-supported
PCORnet.36,37 A distributed research network allows for data
collection and local analyses to be conducted within each
participating partner’s infrastructure. These data are then
aggregated and analyzed across partner registries. This
distributed structure thus avoids the difficulties with data
security, patient privacy, and governance inherent in a single
registry structure. At the same time, the structure allows for
greater size and power of the overall registry, an ability to
assess and compare partner practice patterns, greater diversity
in studied patient populations, and an opportunity to assess the
heterogeneity of treatment effect in various real-world settings.
It also lowers barriers to participation in INTERAF and engages
with local AF experts to best identify partner-specific charac-
teristics and challenges in AF management for analysis.
DOI: 10.1161/JAHA.116.004037 Journal of the American Heart Association 5
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In order to effectively manage this distributed research
network, a governance structure will be established to
determine the minimal data elements and standards needed
for partner participation in INTERAF and the technical
specifications necessary to integrate registries. Examples of
necessary data elements include patient and clinical demo-
graphics, AF phenotype (eg, paroxysmal, persistent, perma-
nent) characteristics, relevant clinical comorbidities, stroke
and bleeding risk scores, AF therapies (eg, rate control,
rhythm control, anticoagulation), and relevant concurrent
medications. In addition, efforts to link to other longitudinal
outcomes data will occur to help in understanding the impact
of AF on mortality, quality of life, healthcare utilization, and
costs. Once the individual registry analyses are completed, a
dedicated analytic center will utilize informatics tools to
merge individual analyses into an aggregated result.
Ensuring effective data harmonization and quality across
the partner registries will require significant and ongoing
effort. Participating registries in INTERAF will have differences
in data elements and enrollment criteria (Table 1), which will
require coordination in order to allow for inter-registry
comparisons. For example, the Chinese Atrial Fibrillation
Registry (CAFR) is largely an AF ablation registry, the
European EurObservational Research Programme (EORP) AF
registry enrolls all ambulatory AF patients seen by European
cardiologists, and the US Practice Innovation and Clinical
Excellence (PINNACLE) registry enrolls all AF patients seen in
participating cardiovascular practices. As such, an initial task
of the INTERAF consortium is to harmonize the data elements
between these registries.
Finally, the success of INTERAF will hinge on effective
leadership to organize and accommodate the variety of
research, organizational, and cultural needs anticipated in a
global partnership. In addition, effective ethical and regulatory
oversight will be critical, especially in light of the different
countries, healthcare systems, and research standards
expected to participate in INTERAF. For example, institutional
review board and data privacy standards for each participating
registry will be obtained and unified across participants to
ensure that appropriate patient protection and privacy occurs.
Once these analytic and organizational priorities are
established, then inter-registries research into AF character-
istics, treatments, and outcomes can begin. Table 2 lists the
following areas that the INTERAF partners have identified as
priorities for inter-registry research. These priority areas for
research were generated from INTERAF partner meetings,
after discussion on important areas of focus regarding global
AF care.
Patient Descriptives
The patient characteristics of the initial AF registries partic-
ipating in the INTERAF partnership are listed in Table 3 and
include all patient information collected through the end of
Figure 5. Initial INTERAF partners, by country. APHRS indicates Asia-Pacific Heart Rhythm Society; CAFR, Chinese Atrial Fibrillation Registry;
EORP, EURObservational Research Programme, INTERAF, International Collaborative Partnership for the Study of Atrial Fibrillation; KiCs, Keio
Interhospital Cardiovascular Studies; PINNACLE, Practice Innovation and Clinical Excellence.
DOI: 10.1161/JAHA.116.004037 Journal of the American Heart Association 6
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2015. Of the 8 initial registries participating in the partner-
ship, 7 had begun collecting data by the end of 2015 and the
eighth, the Asia Pacific Heart Rhythm Society registry, will
begin doing so in 2016. The largest patient cohort is the US-
based NCDR registry, followed by the Chinese AF registry. In
general, the majority of patients in all registries were older
than 65 years, with the exception of the Chinese registry,
which is split between those older and younger than 65. The
registries were also generally balanced in patient sex, with the
exception of the majority male (72%) KiCS registry in Japan.
Given the preponderance of registries in the United States,
northern Europe, and Asia, the majority of registry partici-
pants were either white or Asian race. Hypertension was a
common comorbidity in all registries. Coronary artery disease
was much more common in the US PINNACLE registry
population, while HF dominated the European and Balkan
registries.
The majority of patients in the registries had nonvalvular
AF, with a mixture of paroxysmal and permanent AF. AF
treatment consisted of a mixture of rate and rhythm control.
Thromboembolism risk among registry participants was
relatively high, with median CHADS2 and CHA2DS2-VASc
scores indicating a moderate-to-high risk for stroke.
Strategies to reduce this risk were variable, with warfarin
use more common in Europe and the Balkan countries, and
DOACs more common in the Japanese KiCS and Brazilian
PINNACLE registries.
INTERAF Differences From Previous
International Registries
Previously developed AF registries have mostly been derived
from single nation databases, with varied areas of focus
including thromboprophylaxis, rhythm control, and procedural
therapies such as ablation and left atrial appendage closure.5
For example, the Euro Heart Survey involved 35 countries and
3890 patients between 2003 and 2004 to evaluate manage-
ment of oral anticoagulation in AF patients against European
guidelines, but only involved European countries.38 Two of the
largest multinational registries have aimed to enroll >55 000
patients each, and include the Global Anticoagulant Registry
in the Field (GARFIELD) registry evaluating 50 countries
worldwide,39 and the Global Registry on Long-Term Oral
Antithrombotic Treatment in Patients with Atrial Fibrillation
(GLORIA-AF) registry involving 62 centers globally.40 The
focus of both of these registries has mainly been thrombo-
prophylaxis prescription in AF. The Real-life global survey
evaluating patients with atrial fibrillation (REALISE-AF)
enrolled >10 000 patients in 26 countries between 2009
and 2010,41 and the Registry on Cardiac Rhythm Disorders
(RECORDAF) evaluated >5000 patients from 21 countries
worldwide between 2007 and 2008.42 Both REALISE-AF and
RECORDAF were 1-year studies that reported on rhythm-
control therapies in AF patients specifically. The AF ablation
Long-term Registry of EURObservational Research Pro-
gramme has been enrolling patients undergoing AF ablation
in 54 countries since 2010 for long-term outcomes after
ablation.43 The registry’s main focus is procedural outcomes
after AF ablation.
In contrast to these other registries, INTERAF will provide
insight into international AF care across a truly global
spectrum of countries, analyzing a wide variety of treatment
options, with the potential to adapt to temporal changes in
treatment strategies. The global spread of countries repre-
sented by INTERAF is broad, with large representation in the
United States, South America, Europe, and Asia. While the
GARFIELD, GLORIA-AF, and REALISE-AF registries had a
similar multinational representation, INTERAF has the advan-
tage of larger numbers of AF patients from North America and
Asia, providing power for some of the largest global analyses
performed regarding treatment of AF patients. As a contem-
porary global registry that will continue to collect data
longitudinally, INTERAF will be able to capture all types of oral
anticoagulation strategies (warfarin versus DOACs), and
rhythm-control strategies (antiarrhythmic drug medications
Table 2. INTERAF Research Priorities
1. Global and regional comparisons of overall age, sex, and racial/
ethnic characteristics of AF populations
2. Global and regional comparisons of AF management, including
both pharmacologic and nonpharmacologic approaches to heart
rate and rhythm control
3. Global and regional comparisons of pharmacologic and
nonpharmacologic approaches to thromboembolism prevention
4. Global and regional determinants of antithrombotic therapy and
effective anticoagulation control
5. Global and regional outcomes associated with AF management
practices
6. Comparison and predictors of embolic and bleeding events
associated with AF and its management
7. Time trends in use of various treatment strategies in different
healthcare systems
8. Impact of local health systems on AF care
9. Resource utilization for AF care
10. Patterns of AF care as a function of national and international
guideline recommendations
11. Comparison of “real world” AF populations to those studied in AF
clinical trials
12. Global and regional predictors of high-quality AF management
13. Quality improvement initiatives for AF care and outcomes, with a
focus on those elements that can be successfully translated
across countries and geographic regions
AF indicates atrial fibrillation; INTERAF, International Collaborative Partnership for the
Study of Atrial Fibrillation.
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and ablation) to allow for a broad spectrum of treatment
analyses; most other global registries have been devised to
focus only on a specific treatment protocol. Another advan-
tage of INTERAF compared to other global registries will be
planned ongoing shared data collection and analyses, which
will not be limited by a specific end date, to allow for evolution
of the global registry, including the countries that participate
in sharing data. By using a distributive analytic method to
allow for data collection and analyses, and expanding
information collected to several different aspects of AF care,
INTERAF would be poised to provide longitudinal information
on practice patterns, and track changes over time as a
comprehensive global AF registry.
Limitations
The proposed project should be viewed in light of the following
limitations. First, each of themultinational registries included in
INTERAF have previously identified important covariates to
prospectively collect, which may not be completely duplicative.
However, we specifically have included and will analyze
universally important characteristics and comorbidities that
have a common interest related to AF. Although this may seem
to produce a challenge with data organization, we have
specifically chosen a distributed analytic method by which
local analyses may be conducted by each participating registry,
and then analyzed across all partner registries. Second,
differences in data element definition or inclusion criteria for
each country’s specific registry may lead to heterogeneity in
the overall patient population studied. For example, the
percentage of valvular versus nonvalvular as well as paroxysmal
versus persistent AF differed across each specific registry, and
AF patients from specific countries appeared to have more
frequent comorbidities, potentially due to differences in data
element definitions. Finally, each registry within INTERAF will
have differences in the type of outcomes collected, as well as
frequency and timeframe of patient follow-up. While this may
limit the types of specific treatment strategies able to be
compared, INTERAF will focus on those outcomes and treat-
ment strategies that have universal availability of data across
specific registries to allow for analytic integrity.
Future Directions
The initial organization and goals of INTERAF, as outlined
above, are only the beginning of efforts to better characterize
and improve global AF care. Future directions for the initiative
will include continued data harmonization across country
partners and improvements in data collection. Moreover,
attempts to validate country-specific observations, risk strat-
ification schemes, and outcomes may be attempted, in orderTa
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to identify generalizability of previously established research
findings to a multinational AF population, as has been
previously performed examining acute kidney injury, bleeding,
and mortality in Japanese patients undergoing percutaneous
coronary intervention.44,45 Another important effort will
involve INTERAF expansion to include a wide variety of
clinical registries and participating countries, with special
emphasis on registries in the developing world, where little
information about AF care and outcomes currently exists.
Efforts to expand the partnership are under way, and we
anticipate partners from areas such as the Middle East, Africa,
Central America, and Australia.
Conclusions
We present the INTERAF, a worldwide collaboration for
observational study of AF. This project can provide a global
platform for investigators and countries to study AF popula-
tions, treatments, and outcomes and support country-specific
and international efforts to optimize global care for the large
and growing population of AF patients. As insights from the
consortium accumulate, INTERAF will develop mechanisms to
understand regional variation in practice for AF management,
with a particular focus on understanding those practices,
which can be shared globally.
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